Roche's £90,000 Kadcyla price tag too high
This article was originally published in Scrip
Roche's breast cancer dug Kadcyla (trastuzumab emtansine) is too expensive for general use on the UK's National Health Service, says NICE chief executive Sir Andrew Dillon.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.